Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1

Table 1

Univariate analysis of the prognosis of the enrolled patients.

Clinicopathologic variable	N = 67	Median DFS (months)	HR	95% CI	value
Tumour type	Patient group
Squamous cell carcinoma	29	16.00	0.6841	0.3754–1.247	0.2151
Adenocarcinoma	36	14.00
Others (not included in statistical analysis)	2
Stage
I	28	20.00
II	20	16.00			0.5412
III	19	14.00
Age, years
>52	32	16.50	0.8897	0.4925–1.607	0.6984
≤52	35	16.00
Sex
Male	51	16.00	1.096	0.5540–2.169	0.7918
Female	16	20.00
Whether to detect the expression of three genes
Yes	39	16.00	0.6693	0.3616–1.239	0.2011
No	28	12.50
Treatment
Gemcitabine	31	16.00	1.540	0.8447–2.806	0.1588
Paclitaxel	36	22.5